POLYCYSTIC KIDNEY DISEASE

Polycystic Kidney Disease — the most common life-threatening genetic disease, affecting 1 in 400-1,000, where the specific PKD1 or PKD2 genotype predicts kidney failure timeline by decades and determines tolvaptan eligibility.

Whole genome sequencing resolves the complete PKD1 gene — including accurate mapping through its 6 pseudogenes that confound standard sequencing — and PKD2, providing the genotype that predicts ESRD timeline and treatment response.

PKD1
PKD2

About this condition

Polycystic Kidney Disease

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease and one of the most common life-threatening genetic conditions, affecting approximately 1 in 400-1,000 people — an estimated 12.5 million individuals worldwide. ADPKD is caused by pathogenic variants in PKD1 (~78% of cases, chromosome 16p13.3) or PKD2 (~15%, chromosome 4q22.1), encoding polycystin-1 and polycystin-2 respectively. These proteins form a calcium-permeable channel complex that senses fluid flow in the primary cilium of renal epithelial cells. Progressive bilateral renal cyst development leads to massive kidney enlargement and eventual end-stage renal disease.

ADPKD causes progressive bilateral renal cyst growth over decades, producing flank pain, hematuria, hypertension, urinary tract infections, and nephrolithiasis. Hepatic cysts develop in approximately 80% of patients and are typically asymptomatic but can cause massive hepatomegaly in some women. Intracranial aneurysms occur in approximately 8% of ADPKD patients (vs 2-3% in the general population) — rupture causes subarachnoid hemorrhage with high mortality. Mitral valve prolapse, colonic diverticulae, and inguinal hernias are associated features. The mean age of ESRD is approximately 54 years for PKD1 and 74 years for PKD2 — a 20-year difference determined entirely by genotype.

Tolvaptan (Jynarque), a vasopressin V2 receptor antagonist, was FDA-approved in 2018 for ADPKD in adults at risk of rapid progression. Tolvaptan reduces the rate of total kidney volume growth and slows eGFR decline, delaying ESRD. The FDA label specifically targets rapidly progressing ADPKD — typically PKD1 truncating variants, which produce the fastest progression. The Mayo imaging classification (htTKV) combined with molecular genotype provides the most accurate risk stratification for tolvaptan treatment decisions. Additionally, screening for intracranial aneurysms (brain MRA) is recommended for ADPKD patients with family history of aneurysm or subarachnoid hemorrhage.

PKD1 truncating variants (frameshift, nonsense, splice disrupting) cause ESRD approximately 12 years earlier than PKD1 non-truncating (missense) variants. The specific variant type refines prognosis beyond simply PKD1 vs PKD2.

Gene locus: PKD1 (16p13.3), PKD2 (4q22.1)

PKD1 has 6 highly homologous pseudogenes on the same chromosome that confound standard sequencing. Long-read-informed whole genome sequencing maps through the pseudogene region to identify true PKD1 pathogenic variants.

PKD1 vs PKD2 determines a 20-year difference in ESRD onset — genotype is the strongest predictor of renal prognosis

Mean age of ESRD is approximately 54 years for PKD1 pathogenic variants and approximately 74 years for PKD2 pathogenic variants — making molecular genotype the single strongest predictor of renal prognosis in ADPKD, superior to baseline kidney volume, age, or eGFR slope alone. Furthermore, PKD1 truncating variants cause ESRD approximately 12 years earlier than PKD1 non-truncating variants, adding additional prognostic refinement. This information directly affects clinical decision-making: tolvaptan initiation timing, blood pressure targets, family planning discussions, and living donor kidney transplant timing all depend on the predicted ESRD timeline.

Tolvaptan eligibility requires rapid progression assessment — genotype is a key component of the risk model

The FDA label for tolvaptan (Jynarque) targets ADPKD patients at risk of rapid progression. The PROPKD score, which incorporates molecular genotype (PKD1 truncating = highest score) alongside clinical variables (sex, hypertension onset, urological events), predicts rapid progression with validated accuracy. Patients with a low PROPKD score (typically PKD2 or PKD1 non-truncating variants) may not be candidates for tolvaptan — avoiding the medication's significant side effects (polyuria, polydipsia, hepatotoxicity monitoring) in patients unlikely to benefit. Whole genome sequencing provides the molecular input for this risk-stratification model.

Polycystic Kidney Disease — the most common life-threatening genetic disease, affecting 1 in 400-1,000, where the specific PKD1 or PKD2 genotype predicts kidney failure timeline by decades and determines tolvaptan eligibility.

Polycystic Kidney Disease

PKD1 has 6 highly homologous pseudogenes on the same chromosome that confound standard sequencing. Long-read-informed whole genome sequencing maps through the pseudogene region to identify true PKD1 pathogenic variants.

PKD1 vs PKD2 determines a 20-year difference in ESRD onset — genotype is the strongest predictor of renal prognosis

Tolvaptan eligibility requires rapid progression assessment — genotype is a key component of the risk model

Others in Rare Diseases

One test. A lifetime of answers.